Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 2/20 | 0.30 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8553557 | 0.90 | — | — | |
| SCHEMBL4373290 | 0.79 | — | — | |
| SCHEMBL77046 | 0.78 | FAAH (0.52) | CA2RELAFAAH | |
| SCHEMBL1679338 | 0.78 | FAAH (0.52) | CA2RELAFAAH | |
| SCHEMBL6780714 | 0.78 | FAAH (0.52) | CA2RELAFAAH | |
| SCHEMBL3261095 | 0.78 | FAAH (0.52) | CA2RELAFAAH | |
| SCHEMBL24052340 | 0.76 | RELA (0.44) | LMNATSHRCA2RELA | |
| SCHEMBL7101333 | 0.76 | ALDH1A1 (0.36) | ALDH1A1TSHRKDM4ERELAFAAH | |
| SCHEMBL12781131 | 0.76 | RELA (0.30) | RELAFAAH | |
| SCHEMBL1656935 | 0.76 | RELA (0.44) | LMNATSHRCA2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2675803-A1 | MACROCYCLIC INTEGRASE INHIBITORS FOR USE IN THE TREATMENT OF FELINE IMMUNODEFICIENCY VIRUS | Elanco Animal Health Ireland Limited (IE) | 2013-12-25 | — | — | EP | disclosed |
| EP-2488521-B1 | MACROCYCLIC INTEGRASE INHIBITORS | ELANCO ANIMAL HEALTH IRELAND (IE) | 2013-12-18 | — | — | EP | disclosed |
| CN-103459390-A | Macrocyclic integrase inhibitors for use in the treatment of feline immunodeficiency virus | ELANCO ANIMAL HEALTH IRELAND | 2013-12-18 | — | — | CN | disclosed |
| US-20130296330-A1 | MACROCYCLIC INTEGRASE INHIBITORS FOR USE IN THE TREATMENT OF FELINE IMMUNODEFICIENCY VIRUS | ELANCO ANIMAL HEALTH IRELAND LIMITED (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130296330-A1 | MACROCYCLIC INTEGRASE INHIBITORS FOR USE IN THE TREATMENT OF FELINE IMMUNODEFICIENCY VIRUS | ELANCO ANIMAL HEALTH IRELAND LIMITED (US) | 2013-11-07 | — | — | US | disclosed |
| US-8497270-B2 | Macrocyclic integrase inhibitors | ELANCO ANIMAL HEALTH IRELAND LIMITED (US) | 2013-07-30 | — | — | US | disclosed |
| US-8497270-B2 | Macrocyclic integrase inhibitors | ELANCO ANIMAL HEALTH IRELAND LIMITED (US) | 2013-07-30 | — | — | US | disclosed |
| WO-2012112345-A1 | MACROCYCLIC INTEGRASE INHIBITORS FOR USE IN THE TREATMENT OF FELINE IMMUNODEFICIENCY VIRUS | ELANCO ANIMAL HEALTH IRELAND LIMITED (US) | 2012-08-23 | — | — | WO | disclosed |
| EP-2488521-A1 | MACROCYCLIC INTEGRASE INHIBITORS | Elanco Animal Health Ireland Limited (IE) | 2012-08-22 | — | — | EP | disclosed |
| EP-2487176-A1 | Macrocyclic integrase inhibitors for use in the treatment of feline immunodeficiency virus | Elanco Animal Health Ireland Limited (IE) | 2012-08-15 | — | — | EP | disclosed |
| CN-102574854-A | Macrocyclic integrase inhibitors | ELANCO ANIMAL HEALTH IRELAND | 2012-07-11 | — | — | CN | disclosed |
| US-20120172367-A1 | MACROCYCLIC INTEGRASE INHIBITORS | ELANCO ANIMAL HEALTH IRELAND LIMITED (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120172367-A1 | MACROCYCLIC INTEGRASE INHIBITORS | ELANCO ANIMAL HEALTH IRELAND LIMITED (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120172367-A1 | MACROCYCLIC INTEGRASE INHIBITORS | ELANCO ANIMAL HEALTH IRELAND LIMITED (US) | 2012-07-05 | — | — | US | disclosed |
| WO-2011045330-A1 | MACROCYCLIC INTEGRASE INHIBITORS | TIBOTEC PHARMACEUTICALS (IE) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296330-A1 | MACROCYCLIC INTEGRASE INHIBITORS FOR USE IN THE TREATMENT OF FELINE IMMUNODEFICIENCY VIRUS | FIP1L1, PIM1, TYMP | LMNA 2097/4885ALDH1A1 388/4885HSD17B10 1585/4885 |
| US-20120172367-A1 | MACROCYCLIC INTEGRASE INHIBITORS | CCNI, CCNY, CDK7 | LMNA 1755/4885ALDH1A1 2498/4885HSD17B10 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.